GlassScriptPhysician profile
Martha Moreno
NPI 1083370688
$4,265.89
in general payments reported to CMS, 2019-2025
31 companies · $871 in 2025
The $871 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $517 · 2023: $955 · 2024: $1,683 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,508.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $633.79 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $547.17 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $381.93 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $331.42 | 2022-2024 | Caplyta |
| Amgen INC. | $240.18 | 2023-2024 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $240.00 | 2021 | |
| Ironwood Pharmaceuticals, INC | $218.66 | 2023-2024 | Linzess |
| Glaxosmithkline, LLC. | $171.59 | 2023-2024 | Arexvy, Nucala, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.83 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $90.45 | 2022 | |
| Pfizer INC. | $78.71 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $65.39 | 2025 | Rexulti |
| Novo Nordisk INC | $61.92 | 2024 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $46.05 | 2023-2025 | Gemtesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42.55 | 2025 | Voquezna |
| Philips North America LLC | $40.69 | 2025 | Vest Therapy Und |
| Dexcom, INC. | $35.21 | 2024 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $34.74 | 2024 | Twirla |
| Mylan Specialty L.P. | $28.92 | 2024 | Yupelri |
| Nevro Corp. | $27.76 | 2022 | |
| Pulmonx Corporation | $23.40 | 2024 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Hologic Sales and Service, LLC | $22.25 | 2025 | Aptima, Thinprep 2000 Processor |
| Idorsia Pharmaceuticals US INC | $22.17 | 2022 | |
| Shield Therapeutics INC | $20.13 | 2025 | |
| Kyowa Kirin, INC. | $18.69 | 2025 | |
| Abbott Laboratories | $17.82 | 2023 | Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $17.52 | 2025 | |
| Seqirus USA INC | $17.00 | 2025 | Fluad, Flucelvax |
| Verrica Pharmaceuticals INC. | $16.44 | 2024 | Ycanth |
| Novartis Pharmaceuticals Corporation | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.